In a large-scale global study, Southey et al. [10] detected the mutation of PALB2 (partner and localizer of BC susceptibility gene 2), CHEK2 (checkpoint kinase 2), and ATM (ataxia telangiectasia-mutated gene), their study was deemed to be the world’s first research which demonstrated that rare genetic mutations also contributed to relatively high risks of BC. The gene discussed is CHEK2; the disease is breast cancer.